Pipeline Drugs Lining Up To Compete In Major PAH Market
A spate of news at the start of this year regarding therapies for pulmonary arterial hypertension (PAH) threw fresh light on the disorder - and might put eventual pressure on the Swiss firm Actelion Ltd., which markets the only approved oral therapy: Tracleer (bosentan), the dual endothelin receptor antagonist given market clearance by the FDA in 2001.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter